Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...

Neurocrine Biosciences has sealed a nearly $3bn acquisition of a biotech behind the treatment for a rare genetic form of ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages ...

Samarth Kulkarni is one of the most consequential figures in modern biotechnology, widely recognised for his role in transforming CRISPR Therapeutics from an early-stage gene-editing company into the ...

Prospectively designed for scalability and re-dosability, Immusoft’s engineered B cells represent the next generation of ...

MIT Technology Review discovered that the stealth startup’s founder John Schloendorn also pitched a startling, medically ...

FibroBiologics, Inc., (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Biomedical researchers have designed an injectable microgel to help reduce bleeding in infants who require surgical care. In an animal model, the engineered microgel reduced bleeding by at least 50%.